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Development of therapeutics for treatment of ocular diseases is a challenging task for 41 pharmaceutical formulators and scientists. This is because of the sensitivity of the ocular tissues 1% or less of the total dose to be administered. Thus, drug delivery modalities that can increase 48 drug bioavailability (extending the duration of release, decreasing the amount of drug delivered, A c c e p t e d M a n u s c r i p t 4 minimizing systemic exposure and improving patient compliance and adherence) will certainly 50 offer many advantages over conventional eye drops [1, 2] . Some of these approaches include use 51 of mucoadhesives, prodrugs, nanospheres, liposomes, inclusion of permeability enhancers, 52 implants and punctal or punctum plugs (PPs). This review will focus on the ocular applications 53 of PPs. First, it reviews the use of PPs as a medical device initially developed to physically block 54 the puncta of the eye to treat DES. Second, it reviews the application of PPs for drug delivery to 55 the anterior segment of the eye.
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Dry eye syndrome
57
DES or keratoconjunctivitis sicca is one of the most common ocular disorders frequently 58 discussed in the office of eye-care specialists. In the USA, the average annual cost of managing a 59 patient with DES was US$783 (or US$3.3 billion in total) in 2011. Furthermore, from a societal 60 perspective it was estimated that DES costs US$11 302 per patient (or US$55.4 billion overall) 61 in the USA [3] . The symptoms of DES often include dryness, photophobia, burning and stinging, 62 itching, eye fatigue, pain and redness (hyperemia) [4, 5] . DES is estimated to affect between 14% 63 and 33% of the population worldwide, henceforth it is a significant public health concern [6] .
64
The pathophysiology of DES usually includes poor production of the ocular tear film and 
Treatment of DES
101
The results indicated that punctal plugs were significantly better at improving dry eye symptoms 
106
PPs are either semi-permanent or temporary depending on the material used for their preparation. Semi-permanent PPs either dislodge spontaneously or should be removed by a physician. Plugs 110 fabricated using collagen dissolve within four to seven days; or certain polymer-based plugs last 111 for variable periods of time ranging from three days to six months [13, 24, 25] . Table 1 The latanoprost PP delivery system (L-PPDS) was recently developed for controlled elution of A c c e p t e d M a n u s c r i p t 9 PP and this reservoir has an opening through which drug will be released after coming into Ophthalmics) spontaneous loss happened in 14.7% after three months, 27.3% after one year and 228 36.8% after two years [45] . In another study involving the modified Freeman 'tapered-shaft' 229 plug (Eagle Vision) and SoftPlug (OASIS Medical), it was reported that 47% spontaneous loss 230 occurred at six months with the majority being lost in the initial three months of the study [24] .
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The reasons for PP extrusion were attributed to mucosal dissection by the plug edges leading to 
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